Welcome
Support Centre
02 September 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A phase III, randomised, double blind, multicentre study to evaluate the safety and efficacy of dalbavancin versus linezolid in the treatment of complicated skin and soft tissue infections with suspected gram-positive bacterial pathogens
ISRCTN ISRCTN63718248
ClinicalTrials.gov identifier
Public title A phase III, randomised, double blind, multicentre study to evaluate the safety and efficacy of dalbavancin versus linezolid in the treatment of complicated skin and soft tissue infections with suspected gram-positive bacterial pathogens
Scientific title
Acronym N/A
Serial number at source N0123138529
Study hypothesis To compare how safe the trial medication dalbavancin is when compared to a standard of care treatment in patients suffering from complicated skin infections
Ethics approval Not provided at time of registration
Study design Phase III randomised double blind multicentre study
Countries of recruitment United Kingdom
Disease/condition/study domain Infections and Infestations: Gram-positive bacterial pathogens
Participants - inclusion criteria 1. Patients having infection consistent with complicated skin and soft tissue infection either involving deeper soft tissue or requiring significant surgical intervention
2. Patients to require 24hrs of parental therapy for suspected gram-positive complicated skin
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 30/09/2003
Anticipated end date 05/08/2004
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions Dalbavancin vs standard care
Primary outcome measure(s) The clinical and microbiological responses to therapy.
Secondary outcome measure(s) Not provided at time of registration
Sources of funding University Hospitals of Leicester NHS Trust (UK)
Trial website
Publications
Contact name Dr  Martin  Wiselka
  Address University Hospitals of Leicester
c/o Research and Development Office
Leicester General Hospital NHS Trust
  City/town Leicester
  Zip/Postcode LE1 4PW
  Country United Kingdom
  Tel +44 (0)116 258 4109
  Fax +44 (0)116 258 4226
  Email martin.wiselka@uhl-tr.nhs.uk
Sponsor Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)
  Address The Department of Health,
Richmond House,
79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)20 7307 2622
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.dh.gov.uk/Home/fs/en
Date applied 30/09/2004
Last edited 29/06/2010
Date ISRCTN assigned 30/09/2004
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 ISRCTN unless otherwise stated.


BioMed Central